Cleared Traditional

K831773 - MAI HYDROSEAL IMPLANT FOR SCLERAL BUCK (FDA 510(k) Clearance)

Class II Ophthalmic device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K831773 · Bcd Products, Inc. · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 1983
Decision
75d
Days
Class 2
Risk

K831773 is an FDA 510(k) clearance for the MAI HYDROSEAL IMPLANT FOR SCLERAL BUCK. Classified as Implant, Absorbable, (scleral Buckling Methods) (product code HQJ), Class II - Special Controls.

Submitted by Bcd Products, Inc. (Walker, US). The FDA issued a Cleared decision on August 16, 1983 after a review of 75 days - a notably fast clearance cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.3300 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Bcd Products, Inc. devices

Submission Details

510(k) Number K831773 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 02, 1983
Decision Date August 16, 1983
Days to Decision 75 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
35d faster than avg
Panel avg: 110d · This submission: 75d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code HQJ Implant, Absorbable, (scleral Buckling Methods)
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 886.3300
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ophthalmic devices follow this clearance model.